Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
2008

Using PPAR Agonists to Lower Heart Disease Risk

publication Evidence: moderate

Author Information

Author(s): Jennifer G. Robinson

Primary Institution: University of Iowa

Hypothesis

Can PPAR agonists effectively reduce cardiovascular risk?

Conclusion

PPAR agonists show mixed results in reducing cardiovascular events, with some increasing risks of serious adverse effects.

Supporting Evidence

  • Gemfibrozil showed a significant reduction in coronary heart disease risk despite no effect on LDL.
  • Pioglitazone reduced ischemic events but increased heart failure risk.
  • Rosiglitazone may increase the risk of heart disease and death.

Takeaway

Some medicines that help with blood sugar and fat levels might not help your heart and could even make things worse.

Methodology

Review of randomized controlled trials and observational studies on PPAR agonists.

Potential Biases

Potential for publication bias and selective reporting in the studies reviewed.

Limitations

The studies reviewed had mixed results and varied populations, making it hard to draw clear conclusions.

Participant Demographics

Included subjects with diabetes and cardiovascular disease.

Digital Object Identifier (DOI)

10.1155/2008/891425

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication